Continuity of care rather than an abrupt stop once the trial ends
In the long struggle against rare kidney disease, a small biotech company has chosen not to abandon its trial participants at the threshold of uncertainty. Dimerix has opened post-trial access pathways for DMX-200, allowing patients with focal segmental glomerulosclerosis to continue receiving the investigational therapy through compassionate use and expanded access programs while the world awaits regulatory judgment. It is a gesture that acknowledges what clinical timelines often obscure: that behind every data point is a person whose kidneys are quietly failing, and for whom waiting is not a neutral act.
- Patients with a scarring kidney disease that steadily erodes function now face the precarious interval between trial completion and regulatory decision — a gap that can stretch years.
- Without formal approval, an abrupt end to experimental treatment would force patients back toward options their doctors have already deemed insufficient.
- Dimerix has activated expanded access and compassionate use pathways, allowing physicians to continue DMX-200 where no suitable alternatives exist and medical necessity is clear.
- Logistics vary by region — commercial partners manage supply in their territories while Dimerix covers the rest — but safety monitoring, not efficacy measurement, is the program's primary obligation.
- The arrangement carries no guarantee: it is a legal and ethical bridge, not a destination, and the drug's broader future hinges entirely on ACTION3's forthcoming efficacy results.
Dimerix has created a way for patients to keep taking DMX-200 after completing the ACTION3 Phase 3 trial, so long as their physicians judge the drug medically necessary and no better options are available. The disease in question — focal segmental glomerulosclerosis — scars the kidney's filtering structures and frequently progresses to kidney failure, leaving patients with few approved treatments and little time to spare.
DMX-200 works by blocking a specific immune pathway involved in kidney damage. In the ACTION3 trial, patients already on standard therapy were randomized to the drug or placebo for two years, with researchers tracking protein loss in urine and the rate of kidney function decline. For those who have spent that time in the trial, the prospect of an abrupt stop — followed by months or years of regulatory waiting — is not merely inconvenient; it is medically consequential.
The post-trial access program operates differently depending on geography. Where Dimerix has commercial partners, those companies manage supply and program logistics. In unpartnered regions, Dimerix handles access directly. The company was careful to distinguish these pathways from regulatory approval: compassionate use and expanded access exist in a legal space designed for situations where standard treatments have failed, not as a substitute for the formal approval process.
Data collected during this period will focus on safety rather than efficacy — a practical reality, since the structured conditions of a clinical trial no longer apply. Chief Medical Officer David Fuller described the decision as honoring the commitment to patients who have already invested hope and time in the program. The true reckoning, however, will arrive with ACTION3's efficacy results, which will determine whether DMX-200 earns a path to broad regulatory approval or remains confined to these narrow, carefully bounded access programs.
Dimerix has opened a pathway for patients to keep taking DMX-200 after they finish the ACTION3 Phase 3 trial, provided their doctors believe the drug remains medically necessary and no better options exist. The arrangement allows people with focal segmental glomerulosclerosis—a rare kidney disease that scars and damages the filtering units of the kidneys—to continue receiving the investigational therapy through expanded access or compassionate use programs, depending on where they live.
The drug itself is a CCR2 antagonist, a type of molecule designed to block a specific immune pathway implicated in kidney damage. In the ACTION3 trial, patients already taking an angiotensin II receptor blocker are randomly assigned to receive either DMX-200 or a placebo for two years, with researchers measuring whether the drug reduces protein loss in the urine and slows the decline of kidney function. For people with FSGS, which has limited treatment options and often progresses to kidney failure, the chance to continue an experimental therapy while waiting for regulatory decisions carries real weight.
How the post-trial access will work depends on local regulations and commercial arrangements. In territories where Dimerix has partnered with other companies, those partners will handle the logistics of getting the drug to patients and managing the program. In regions without a commercial partner, Dimerix itself will manage supply and access. The company emphasized that these pathways—expanded access and compassionate use—are not the same as regulatory approval. They exist in a legal gray zone, allowing patients to receive investigational drugs outside of formal trials when standard treatments have failed or don't exist.
Data collection from patients in the post-trial access program will focus primarily on safety. This is a practical constraint: without the structured protocols of a clinical trial, gathering rigorous efficacy data becomes difficult. What matters most at this stage is ensuring the drug doesn't cause unexpected harm as people continue to take it. Dimerix's Chief Medical Officer, David Fuller, framed the decision as a commitment to patients who have already invested time and hope in the clinical program, giving them continuity of care rather than an abrupt stop once the trial ends.
The announcement reflects a broader shift in how biotech companies think about the period between trial completion and regulatory approval—a gap that can stretch months or years. For diseases like FSGS, where kidney function declines steadily and irreversibly, that gap matters. Patients and their doctors face a choice: stop the experimental drug and watch the disease progress, or pursue access through compassionate use pathways that exist precisely for situations where no approved alternatives work. Dimerix's decision to formally support these pathways removes some of the friction and uncertainty from that choice, though it does not guarantee approval or wider availability. The real test will come when ACTION3 produces its efficacy results, data that will determine whether DMX-200 moves toward regulatory approval or remains confined to these narrow access programs.
Notable Quotes
We are committed to ensuring that patients with FSGS, who have participated in our clinical program, have the opportunity to continue treatment with DMX-200 where appropriate.— Dr David Fuller, Dimerix Chief Medical Officer
The Hearth Conversation Another angle on the story
Why does a company announce post-trial access before the trial is even finished? Doesn't that signal they're already thinking the drug might not get approved?
Not necessarily. It's more practical than that. FSGS patients lose kidney function steadily. If someone's been on DMX-200 for two years in the trial and their kidney function has stabilized, stopping abruptly when the trial ends could be harmful. The company is saying: we'll let you keep going while we wait for regulatory decisions. It's about continuity, not confidence or doubt.
But if the drug works, wouldn't they just fast-track approval? Why would patients need compassionate use?
Regulatory approval takes time, even for promising drugs. The trial might show benefit, but regulators will want to review the data carefully, ask questions, maybe request more information. That process can take months. Compassionate use bridges that gap—it's a legal mechanism that says, "This person needs this drug now, and their doctor agrees it's appropriate."
Who actually decides if a patient gets access? Is it Dimerix, the doctor, or someone else?
It's a conversation between the patient and their doctor. They determine together whether continuing makes sense. Then the doctor applies through the appropriate channel—expanded access in the US, for example. Dimerix and its partners handle the paperwork and supply, but they're not gatekeeping medical decisions.
The company says they're only collecting safety data, not efficacy data. Doesn't that mean they're giving up on learning whether the drug actually works?
They already have efficacy data from the trial itself. What they can't do in post-trial access is run a controlled study—there's no placebo group, no standardized protocols. Safety monitoring is what's feasible and what matters most: Does the drug cause unexpected harm in the real world? That's valuable information, even if it's not as rigorous as trial data.
So this announcement doesn't tell us anything about whether DMX-200 will actually be approved?
Not directly. It tells us Dimerix expects some patients will want to keep taking it after the trial ends, and they're prepared to support that. The real answer about approval comes when ACTION3 releases its results—whether the drug actually reduced proteinuria and slowed kidney decline compared to placebo.